Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Net Cash Flow (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Net Cash Flow data on record, last reported at -$19.5 million in Q4 2020.

  • For Q4 2020, Net Cash Flow fell 175.06% year-over-year to -$19.5 million; the TTM value through Dec 2020 reached -$230.7 million, changed N/A, while the annual FY2024 figure was $27.3 million, 271.04% up from the prior year.
  • Net Cash Flow reached -$19.5 million in Q4 2020 per KLRS's latest filing, up from -$228.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $26.0 million in Q4 2019 and bottomed at -$228.3 million in Q3 2020.